Rigrodsky & Long, P.A. Announces Investigation Of Trius Therapeutics, Inc. Buyout
31 Julho 2013 - 2:48PM
Business Wire
Rigrodsky & Long, P.A.:
- Do you own shares of Trius
Therapeutics, Inc. (NASDAQ GM: TSRX)?
- Did you purchase any of your shares
prior to July 30, 2013?
- Do you think the proposed buyout
price is too low?
- Do you want to discuss your
rights?
Rigrodsky & Long, P.A. announces that it is investigating
potential legal claims against the board of directors of Trius
Therapeutics, Inc. (“Trius” or the “Company”) (NASDAQ GM: TSRX)
regarding possible breaches of fiduciary duties and other
violations of law related to the Company’s entry into an agreement
to be acquired by Cubist Pharmaceuticals, Inc. (“Cubist”) (NASDAQ
GS: CBST) in a transaction valued at approximately $818
million.
Click here to learn more:
http://www.rigrodskylong.com/investigations/trius-therapeutics-inc-tsrx.
Under the terms of the agreement, public shareholders of Trius
will receive $13.50 per share in cash for each share of Trius they
own. In addition to the cash consideration, Trius shareholders
would also receive one Contingent Value Right for each Trius share
they own, which could yield additional cash consideration of up to
$2.00 per share.
The investigation concerns whether Trius’s board of directors
failed to adequately shop the Company and obtain the best possible
value for Trius’s shareholders before entering into an agreement
with Cubist. According to Yahoo! Finance, at least one analyst has
set a price target for Trius stock at $20.00 per share.
If you own the common stock of Trius and purchased your shares
before July 30, 2013, if you have information or would like to
learn more about these claims, or if you wish to discuss these
matters or have any questions concerning this announcement or your
rights or interests with respect to these matters, please contact
Seth Rigrodsky or Peter Allocco at Rigrodsky & Long, P.A., 825
East Gate Boulevard, Suite 300, Garden City, New York 11530, by
telephone at (888) 969-4242; by e-mail to info@rl-legal.com, or at:
http://www.rigrodskylong.com/investigations/trius-therapeutics-inc-tsrx.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware
and Garden City, New York, regularly prosecutes securities class,
derivative and direct actions, shareholder rights litigation and
corporate governance litigation, on behalf of shareholders in
states and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar
outcome.
Trius Therapeutics, Inc. (MM) (NASDAQ:TSRX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Trius Therapeutics, Inc. (MM) (NASDAQ:TSRX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024